Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use

A prospective study of normal BMI and obese women

Monica Dragoman, Kelsey Petrie, Anupama Torgal, Tiffany Thomas, Serge Cremers, Carolyn L. Westhoff

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background A single study shows that contraceptive vaginal ring (CVR) use for up to 35 days in women with a normal body mass index (BMI) maintains serum hormone levels sufficient to suppress ovulation. This study is intended to confirm those results and to evaluate prolonged CVR use up to 42 days in both normal BMI and obese women. Study Design Twenty women with a normal BMI and 20 obese women enrolled in a prospective open label clinical study of ethinyl estradiol (EE) and etonogestrel (ENG) pharmacokinetics during six weeks of use of a single CVR. Participants underwent twice-weekly evaluations to determine serum hormone concentrations, ovarian follicle development, endometrial thickness and bleeding patterns. Results Thirty-seven women completed follow-up including eighteen women with a normal BMI and nineteen obese women. EE and ENG concentrations remained in therapeutic range for all women. Follicular development and endometrial proliferation were minimal. By the sixth week, 30% of participants reported spotting or bleeding. Conclusions A single CVR used for 6 weeks demonstrates therapeutic serum levels of EE and ENG among women with normal and obese BMI. Women who forget to remove the CVR at day 21 may well have continued contraceptive protection during the next 3 weeks.

Original languageEnglish (US)
Pages (from-to)432-436
Number of pages5
JournalContraception
Volume87
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Female Contraceptive Devices
Contraceptive Agents
Body Mass Index
Prospective Studies
Ethinyl Estradiol
Serum
Hormones
Hemorrhage
Metrorrhagia
Ovarian Follicle
Ovulation
Pharmacokinetics

Keywords

  • Contraceptive vaginal ring
  • Obesity
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use : A prospective study of normal BMI and obese women. / Dragoman, Monica; Petrie, Kelsey; Torgal, Anupama; Thomas, Tiffany; Cremers, Serge; Westhoff, Carolyn L.

In: Contraception, Vol. 87, No. 4, 04.2013, p. 432-436.

Research output: Contribution to journalArticle

Dragoman, Monica ; Petrie, Kelsey ; Torgal, Anupama ; Thomas, Tiffany ; Cremers, Serge ; Westhoff, Carolyn L. / Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use : A prospective study of normal BMI and obese women. In: Contraception. 2013 ; Vol. 87, No. 4. pp. 432-436.
@article{8a27b42ec9dd43b69a74024051971821,
title = "Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: A prospective study of normal BMI and obese women",
abstract = "Background A single study shows that contraceptive vaginal ring (CVR) use for up to 35 days in women with a normal body mass index (BMI) maintains serum hormone levels sufficient to suppress ovulation. This study is intended to confirm those results and to evaluate prolonged CVR use up to 42 days in both normal BMI and obese women. Study Design Twenty women with a normal BMI and 20 obese women enrolled in a prospective open label clinical study of ethinyl estradiol (EE) and etonogestrel (ENG) pharmacokinetics during six weeks of use of a single CVR. Participants underwent twice-weekly evaluations to determine serum hormone concentrations, ovarian follicle development, endometrial thickness and bleeding patterns. Results Thirty-seven women completed follow-up including eighteen women with a normal BMI and nineteen obese women. EE and ENG concentrations remained in therapeutic range for all women. Follicular development and endometrial proliferation were minimal. By the sixth week, 30{\%} of participants reported spotting or bleeding. Conclusions A single CVR used for 6 weeks demonstrates therapeutic serum levels of EE and ENG among women with normal and obese BMI. Women who forget to remove the CVR at day 21 may well have continued contraceptive protection during the next 3 weeks.",
keywords = "Contraceptive vaginal ring, Obesity, Pharmacodynamics, Pharmacokinetics",
author = "Monica Dragoman and Kelsey Petrie and Anupama Torgal and Tiffany Thomas and Serge Cremers and Westhoff, {Carolyn L.}",
year = "2013",
month = "4",
doi = "10.1016/j.contraception.2012.12.001",
language = "English (US)",
volume = "87",
pages = "432--436",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use

T2 - A prospective study of normal BMI and obese women

AU - Dragoman, Monica

AU - Petrie, Kelsey

AU - Torgal, Anupama

AU - Thomas, Tiffany

AU - Cremers, Serge

AU - Westhoff, Carolyn L.

PY - 2013/4

Y1 - 2013/4

N2 - Background A single study shows that contraceptive vaginal ring (CVR) use for up to 35 days in women with a normal body mass index (BMI) maintains serum hormone levels sufficient to suppress ovulation. This study is intended to confirm those results and to evaluate prolonged CVR use up to 42 days in both normal BMI and obese women. Study Design Twenty women with a normal BMI and 20 obese women enrolled in a prospective open label clinical study of ethinyl estradiol (EE) and etonogestrel (ENG) pharmacokinetics during six weeks of use of a single CVR. Participants underwent twice-weekly evaluations to determine serum hormone concentrations, ovarian follicle development, endometrial thickness and bleeding patterns. Results Thirty-seven women completed follow-up including eighteen women with a normal BMI and nineteen obese women. EE and ENG concentrations remained in therapeutic range for all women. Follicular development and endometrial proliferation were minimal. By the sixth week, 30% of participants reported spotting or bleeding. Conclusions A single CVR used for 6 weeks demonstrates therapeutic serum levels of EE and ENG among women with normal and obese BMI. Women who forget to remove the CVR at day 21 may well have continued contraceptive protection during the next 3 weeks.

AB - Background A single study shows that contraceptive vaginal ring (CVR) use for up to 35 days in women with a normal body mass index (BMI) maintains serum hormone levels sufficient to suppress ovulation. This study is intended to confirm those results and to evaluate prolonged CVR use up to 42 days in both normal BMI and obese women. Study Design Twenty women with a normal BMI and 20 obese women enrolled in a prospective open label clinical study of ethinyl estradiol (EE) and etonogestrel (ENG) pharmacokinetics during six weeks of use of a single CVR. Participants underwent twice-weekly evaluations to determine serum hormone concentrations, ovarian follicle development, endometrial thickness and bleeding patterns. Results Thirty-seven women completed follow-up including eighteen women with a normal BMI and nineteen obese women. EE and ENG concentrations remained in therapeutic range for all women. Follicular development and endometrial proliferation were minimal. By the sixth week, 30% of participants reported spotting or bleeding. Conclusions A single CVR used for 6 weeks demonstrates therapeutic serum levels of EE and ENG among women with normal and obese BMI. Women who forget to remove the CVR at day 21 may well have continued contraceptive protection during the next 3 weeks.

KW - Contraceptive vaginal ring

KW - Obesity

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84875275501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875275501&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2012.12.001

DO - 10.1016/j.contraception.2012.12.001

M3 - Article

VL - 87

SP - 432

EP - 436

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 4

ER -